RU2019114940A - Лечение катаплексии - Google Patents

Лечение катаплексии Download PDF

Info

Publication number
RU2019114940A
RU2019114940A RU2019114940A RU2019114940A RU2019114940A RU 2019114940 A RU2019114940 A RU 2019114940A RU 2019114940 A RU2019114940 A RU 2019114940A RU 2019114940 A RU2019114940 A RU 2019114940A RU 2019114940 A RU2019114940 A RU 2019114940A
Authority
RU
Russia
Prior art keywords
formula
enantiomer
compound
predominates
amount
Prior art date
Application number
RU2019114940A
Other languages
English (en)
Russian (ru)
Other versions
RU2019114940A3 (cg-RX-API-DMAC10.html
Inventor
Мойз А. КХАЙРАЛЛАХ
Гари БРИМ
Стефен Э. БАТТС
Original Assignee
ЭРИЭЛ БАЙОФАРМА, ЭлЭлСи
ЭсКей БАЙОФАРМАСЬЮТИКАЛЗ КО., ЛТД.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51530017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2019114940(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ЭРИЭЛ БАЙОФАРМА, ЭлЭлСи, ЭсКей БАЙОФАРМАСЬЮТИКАЛЗ КО., ЛТД. filed Critical ЭРИЭЛ БАЙОФАРМА, ЭлЭлСи
Publication of RU2019114940A publication Critical patent/RU2019114940A/ru
Publication of RU2019114940A3 publication Critical patent/RU2019114940A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/02—Carbamic acids; Salts of carbamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
RU2019114940A 2013-03-13 2014-03-12 Лечение катаплексии RU2019114940A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361778998P 2013-03-13 2013-03-13
US61/778,998 2013-03-13

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2015143610A Division RU2689984C2 (ru) 2013-03-13 2014-03-12 Лечение катаплексии

Publications (2)

Publication Number Publication Date
RU2019114940A true RU2019114940A (ru) 2019-06-28
RU2019114940A3 RU2019114940A3 (cg-RX-API-DMAC10.html) 2019-12-25

Family

ID=51530017

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2019114940A RU2019114940A (ru) 2013-03-13 2014-03-12 Лечение катаплексии
RU2015143610A RU2689984C2 (ru) 2013-03-13 2014-03-12 Лечение катаплексии

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2015143610A RU2689984C2 (ru) 2013-03-13 2014-03-12 Лечение катаплексии

Country Status (21)

Country Link
US (7) US9359290B2 (cg-RX-API-DMAC10.html)
EP (1) EP2968208B1 (cg-RX-API-DMAC10.html)
JP (2) JP6530741B2 (cg-RX-API-DMAC10.html)
KR (1) KR102192554B1 (cg-RX-API-DMAC10.html)
CN (1) CN105431142B (cg-RX-API-DMAC10.html)
AU (1) AU2014248849B2 (cg-RX-API-DMAC10.html)
BR (1) BR112015022197B1 (cg-RX-API-DMAC10.html)
CA (1) CA2905457A1 (cg-RX-API-DMAC10.html)
DK (1) DK2968208T3 (cg-RX-API-DMAC10.html)
ES (1) ES2927675T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20221018T1 (cg-RX-API-DMAC10.html)
HU (1) HUE060060T2 (cg-RX-API-DMAC10.html)
MX (1) MX381381B (cg-RX-API-DMAC10.html)
MY (1) MY177740A (cg-RX-API-DMAC10.html)
PH (1) PH12015502075A1 (cg-RX-API-DMAC10.html)
PT (1) PT2968208T (cg-RX-API-DMAC10.html)
RU (2) RU2019114940A (cg-RX-API-DMAC10.html)
SG (1) SG11201507121RA (cg-RX-API-DMAC10.html)
SI (1) SI2968208T1 (cg-RX-API-DMAC10.html)
TW (2) TWI663971B (cg-RX-API-DMAC10.html)
WO (1) WO2014164969A1 (cg-RX-API-DMAC10.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1890684T3 (pl) * 2005-06-08 2014-05-30 Sk Biopharmaceuticals Co Ltd Leczenie zaburzeń snu i czuwania
AU2010270971B2 (en) 2009-06-22 2015-08-20 Sk Biopharmaceuticals Co., Ltd. Methods for treating or preventing fatigue
RU2019114940A (ru) * 2013-03-13 2019-06-28 ЭРИЭЛ БАЙОФАРМА, ЭлЭлСи Лечение катаплексии
DK3021838T3 (da) 2013-07-18 2020-08-24 Jazz Pharmaceuticals Ireland Ltd Behandling af fedme
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US10195151B2 (en) * 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
CN121202730A (zh) 2016-09-06 2025-12-26 爱尔兰贾兹制药有限公司 (r)-2-氨基-3-苯丙基氨基甲酸酯盐酸盐的制备方法、其组合物及用途
JP7074750B2 (ja) 2016-10-06 2022-05-24 ジャズ ファーマスティカルズ アイルランド リミテッド カルバモイルフェニルアラニノール化合物およびその使用
KR20200016889A (ko) * 2017-06-02 2020-02-17 재즈 파마슈티칼즈 아일랜드 리미티드 과다 졸림증을 치료하기 위한 방법 및 조성물
SG11202000817SA (en) 2017-07-31 2020-02-27 Jazz Pharmaceuticals Ireland Ltd Carbamoyl phenylalaninol analogs and uses thereof
AU2018331326A1 (en) * 2017-09-12 2020-03-19 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of narcolepsy
JP2021512165A (ja) 2018-01-29 2021-05-13 コグノス・セラピューティクス・インコーポレイテッド ボルテゾミブの腫瘍内送達
WO2019245975A1 (en) 2018-06-17 2019-12-26 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
BR112021007019A2 (pt) * 2018-10-15 2021-07-13 Axsome Therapeutics, Inc. uso de reboxetina para tratar narcolepsia
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
BR112021013766A2 (pt) 2019-03-01 2021-09-21 Flamel Ireland Limited Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado
US12616702B2 (en) 2019-12-03 2026-05-05 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
CR20220247A (es) * 2019-12-03 2022-08-18 Axsome Therapeutics Inc Uso de reboxetina para tratar los trastornos del sistema nervioso
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
KR102390194B1 (ko) * 2020-08-03 2022-04-25 셀라이온바이오메드 주식회사 페닐알킬 카바메이트 화합물을 포함하는 Kca3.1채널 매개질환 치료용 조성물
US12582622B2 (en) 2020-10-08 2026-03-24 Jazz Pharmaceuticals Ireland Limited Sodium oxybate to treat idiopathic hypersomnia
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
CN121620365A (zh) 2023-06-29 2026-03-06 艾克萨姆治疗股份有限公司 向哺乳期妇女施用索安非托的方法
EP4766353A1 (en) * 2023-08-21 2026-07-01 Axsome Therapeutics, Inc. USE OF SOLRIAMFETOL FOR THE TREATMENT OF ORPHAN DISEASES
WO2026125068A1 (en) 2024-12-10 2026-06-18 Noucor Health, S.A. Process to obtain solriamfetol hydrochloride
US12565478B1 (en) 2025-01-21 2026-03-03 Axsome Therapeutics, Inc. (S)-2-((S)-(2-ethoxyphenoxy)(phenyl)methyl)-4-nitrosomorpholine

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US178429A (en) * 1876-06-06 Improvement in hulling-machines
NZ314570A (en) 1993-06-10 2000-11-24 Lilly Co Eli Treatment of emesis using tetrahydrobenz[cd]indole-6-carboxamides
KR100197892B1 (ko) 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
KR0173862B1 (ko) 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
US5756817C1 (en) 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
CA2240060C (en) 1996-10-10 2007-07-17 Sk Corporation O-carbamoyl-phenylalaninol compounds, their pharmaceutically useful salts and process for preparing the same
AU4674797A (en) 1996-10-22 1998-05-15 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
US6204245B1 (en) * 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
US20030207857A1 (en) 2001-04-11 2003-11-06 Adam Mavis D. Phenyl heterocyclyl ethers
GB0109103D0 (en) * 2001-04-11 2001-05-30 Pfizer Ltd Novel compounds
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
MXPA06011410A (es) * 2004-03-31 2007-04-20 Johnson & Johnson Compuestos heterociclicos sin imidazol como moduladores de receptor de histamina h3.
BRPI0515645A (pt) * 2004-09-07 2008-03-04 Orphan Medical Inc métodos terapêuticos, composições, compostos e usos de compostos
RU2007119648A (ru) 2004-10-28 2008-12-10 СК Холдингз Ко. Способ лечения депрессии
PL1890684T3 (pl) * 2005-06-08 2014-05-30 Sk Biopharmaceuticals Co Ltd Leczenie zaburzeń snu i czuwania
US8552060B2 (en) 2005-06-22 2013-10-08 Sk Biopharmaceuticals Co., Ltd. Methods for treatment of sexual dysfunction
EP1928451B1 (en) 2005-07-26 2011-12-28 SK Biopharmaceuticals Co., LTD Methods for treating substance-related disorders
FR2903904A1 (fr) * 2006-07-21 2008-01-25 Bioprojet Soc Civ Ile Association de modafinil et d'un antagoniste ou agoniste inverse du recepteur h3
AU2007313017A1 (en) 2006-10-13 2008-04-24 Janssen Pharmaceutica, N.V. Phenylalkylamino carbamate compositions
WO2008055314A1 (en) * 2006-11-10 2008-05-15 Dimerix Bioscience Pty Ltd Thyrotropin releasing hormone receptor-orexin receptor hetero-dimers/-oligomers
AU2010270971B2 (en) * 2009-06-22 2015-08-20 Sk Biopharmaceuticals Co., Ltd. Methods for treating or preventing fatigue
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
EP2496227B1 (en) 2009-11-06 2019-05-22 SK Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
ES2447295T3 (es) 2009-11-06 2014-03-11 Sk Biopharmaceuticals Co., Ltd. Métodos para el tratamiento del trastorno de déficit de atención/hiperactividad
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
RU2019114940A (ru) * 2013-03-13 2019-06-28 ЭРИЭЛ БАЙОФАРМА, ЭлЭлСи Лечение катаплексии

Also Published As

Publication number Publication date
US11713292B2 (en) 2023-08-01
KR102192554B1 (ko) 2020-12-18
AU2014248849B2 (en) 2018-08-30
ES2927675T3 (es) 2022-11-10
HUE060060T2 (hu) 2023-01-28
MY177740A (en) 2020-09-23
US10259780B2 (en) 2019-04-16
MX2015012644A (es) 2016-06-21
US20220017457A1 (en) 2022-01-20
BR112015022197B1 (pt) 2022-06-07
WO2014164969A1 (en) 2014-10-09
US20160250176A1 (en) 2016-09-01
US20230416195A1 (en) 2023-12-28
TWI684450B (zh) 2020-02-11
PH12015502075B1 (en) 2016-01-18
TW201513856A (zh) 2015-04-16
US11072579B2 (en) 2021-07-27
CA2905457A1 (en) 2014-10-09
EP2968208A1 (en) 2016-01-20
US20140275244A1 (en) 2014-09-18
JP2019147830A (ja) 2019-09-05
US20170137375A1 (en) 2017-05-18
US9359290B2 (en) 2016-06-07
CN105431142A (zh) 2016-03-23
JP6530741B2 (ja) 2019-06-12
BR112015022197A2 (pt) 2017-07-18
PH12015502075A1 (en) 2016-01-18
PT2968208T (pt) 2022-10-28
SG11201507121RA (en) 2015-10-29
EP2968208A4 (en) 2016-10-12
TWI663971B (zh) 2019-07-01
RU2015143610A (ru) 2017-04-20
HRP20221018T1 (hr) 2023-01-06
JP2016512531A (ja) 2016-04-28
EP2968208B1 (en) 2022-07-20
RU2015143610A3 (cg-RX-API-DMAC10.html) 2018-03-21
HK1219236A1 (zh) 2017-03-31
TW201919606A (zh) 2019-06-01
MX381381B (es) 2025-03-12
SI2968208T1 (sl) 2023-02-28
RU2689984C2 (ru) 2019-05-30
DK2968208T3 (da) 2022-08-22
KR20150139522A (ko) 2015-12-11
BR112015022197A8 (pt) 2019-11-26
US20190218174A1 (en) 2019-07-18
AU2014248849A1 (en) 2015-10-08
US20250059135A1 (en) 2025-02-20
US9585863B2 (en) 2017-03-07
US12162821B2 (en) 2024-12-10
RU2019114940A3 (cg-RX-API-DMAC10.html) 2019-12-25
CN105431142B (zh) 2019-04-26

Similar Documents

Publication Publication Date Title
RU2015143610A (ru) Лечение катаплексии
JP2016512531A5 (cg-RX-API-DMAC10.html)
PH12018550049A1 (en) Protein kinase inhibitor, preparation method and medical use thereof
JP2012530779A5 (cg-RX-API-DMAC10.html)
EA201100698A1 (ru) Производные тиенотриазолодиазепина, активные в отношении апо а1
RU2015143841A (ru) Ингибиторы hdac
RU2016105436A (ru) Нейроактивные стероиды, композиции и их использование
JP2015511638A5 (cg-RX-API-DMAC10.html)
MA38323B1 (fr) Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale
JP2013533253A5 (cg-RX-API-DMAC10.html)
RU2015107803A (ru) Производные дигидроксипиримидинкарбоновой кислоты и их применение в лечении, облегчении или предотвращении вирусного заболевания
JP2016525121A5 (cg-RX-API-DMAC10.html)
RU2013108348A (ru) Конденсированные гетероарилы и их применение
JP2014511892A5 (cg-RX-API-DMAC10.html)
RU2012101947A (ru) Способы лечения и профилактики усталости
MX2014014106A (es) Derivados de acido 7-oxo-tiazolopiridinocarbonico y su uso en el tratamiento, disminucion o prevencion de una enfermedad viral.
RU2012109554A (ru) Лиганды сигма-рецепторов для предупреждения или лечения боли, вызванной химиотерапией
JP2017538689A5 (cg-RX-API-DMAC10.html)
JP2017505293A5 (cg-RX-API-DMAC10.html)
JP2018510138A5 (cg-RX-API-DMAC10.html)
RU2019121926A (ru) Ингибитор CDK4/6
RU2014129508A (ru) Новая комбинация
JP2019529460A5 (cg-RX-API-DMAC10.html)
RU2020119562A (ru) Хиназолиноновое соединение и его применение
JP2019533007A5 (cg-RX-API-DMAC10.html)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20201012